Top Markets
#1 Wibx Wibx +3.22%
#2 BOT BOT +2.51%
#3 TronBank TronBank +2.45%
#4 Cysic Cysic +2.29%
#5 Starpower Starpower +2.10%
#6 Wiki Cat Wiki Cat +2.02%
#7 The Bitcoin Bull The Bitcoin Bull +1.56%
#8 Tokamak Network Tokamak Network +1.53%
#9 Audiera Audiera +1.45%
#10 SIXSEVEN SIXSEVEN +1.17%
Coin of the day
Wibx Wibx
Settings
Language
ENGLISH
Currency
USD
Theme
PhoenixBio Co., Ltd. PhoenixBio Co., Ltd.

PhoenixBio Co., Ltd.

6190
Rank in Stocks #32811
PhoenixBio Co., Ltd. delivers specialized contract research services to support... PhoenixBio Co., Ltd. delivers specialized contract research services to support drug discovery and development, with a primary focus on the Japanese market. Central to its offerings is the proprietary PXB-mouse, a unique chimeric mouse model featuring a humanized liver, which is critical for various drug development experiments. The company also conducts in vitro analyses utilizing fresh human hepatocytes sourced from PXB-cells. This sophisticated humanized liver model proves invaluable for in vivo studies encompassing gene therapy, NASH/NAFLD drug development programs, anti-viral therapeutic evaluations, DMPK (Drug Metabolism and Pharmacokinetics) and toxicity assessments, and custom transplantation projects. Established in 2002, PhoenixBio maintains its headquarters in Higashihiroshima, Japan.
Share Price
$2.22
Last synced: 2026-08-17
Market Cap
$9.03M
Change (1 day)
-3.13%
Change (1 year)
-24.26%
Country
JP
Trade PhoenixBio Co., Ltd. (6190)

Category

Healthcare
Revenue for PhoenixBio Co., Ltd. (6190)
Revenue in Aug 2026 TTM: 0
According to PhoenixBio Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for PhoenixBio Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE